Merestinib, an inhibitor of MET, AXL (Axl receptor tyrosine kinase), TEK (tunica interna endothelial cell kinase), ROS1, DDR (discoidin domain receptor tyrosine kinase), MKNK (MAP kinase-interacting serine/threonine protein kinase), and FLT3 (Fms-related tyrosine kinase 3), has just finished its first human phase I trial for various advanced cancers, including CRC,338 to determine a suitable dose for the phase II trial. The gene discussed is FLT3; the disease is cancer.